Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants.
Dias A, Brook MN, Bancroft EK, Page EC, Chamberlain A, Saya S, Amin J, Mikropoulos C, Taylor N, Myhill K, Thomas S, Saunders E, Dadaev T, Leongamornlert D, Dyrsø Jensen T, Evans DG, Cybulski C, Liljegren A, Teo SH, Side L; IMPACT study collaborators and Steering Committee; Kote-Jarai Z, Eeles RA.
Dias A, et al. Among authors: mikropoulos c.
BJUI Compass. 2023 Jan 9;4(3):361-373. doi: 10.1002/bco2.156. eCollection 2023 May.
BJUI Compass. 2023.
PMID: 37025481
Free PMC article.